-
Two-Third Patients Experienced No CRS/Neurologic Events Up To Three Days After Yescarta, New Data From LBCL Study Shows
Thursday, February 11, 2021 - 8:14am | 396Read More...Kite, a Gilead Sciences Inc company (NASDAQ: GILD), has announced new data from the ZUMA-1 Phase 1/2 trial of Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL). Gilead will present the results at the...
-
Allergan Continues Educational Strategy Amid FDA's Report Linking Breast Implants To Rare Cancer
Wednesday, March 22, 2017 - 10:19am | 421Read More...Following a Tuesday report by the Food and Drug Administration linking breast implants to anaplastic large cell lymphoma (ALCL), an Allergan plc Ordinary Shares (NYSE: AGN) spokesperson told Benzinga the company is responding to the report with patient and public education. “[We are] working...
-
FDA Links Breast Implants To A Rare Form Of Cancer
Tuesday, March 21, 2017 - 5:26pm | 346Read More...The U.S. Food and Drug Administration announced Tuesday a causal relationship between breast implants and a rare form of cancer, according to an NBC News report. The disease, a form of non-Hodgkin’s lymphoma called anaplastic large cell lymphoma (ALCL), is believed to have killed at least...
